To view this email as a web page, click here.

 
You’re reading Legal Eagle,a column where David J. Goldberg, M.D., J.D., answers your legal questions. This week Dr. Goldberg discusses the risks associated with telemedicine and how far companies can go with off-label drug promotion.
 
What are my liabilities with telemedicine?
Teledermatology can be a major part of some dermatology practices. In this Legal Eagle article, Dr. Goldberg discusses the liability issues surrounding telemedicine that could put you and your practice at risk.
ADVERTISEMENT
 
Off-label drug promotion or education?
How far can drug companies go with off-label promotion? Dr. Goldberg addresses this and more in his latest Legal Eagle column.
 
ADVERTISEMENT
Managing melasma symptoms and patient expectations
In this Dermatology Times podcast, featured physician Seemal Desai, MD, FAAD, details his range of therapeutic combinations — including specific uses of hydroquinone, oral tranexamic acid and chemical peels. Listen to the podcast now.
 
 
Connect with us on Twitter and Facebook for daily updates.
 
ADVERTISEMENT
Our Rx, our responsibility: facing antibiotic resistance
In this Dermatology Times podcast, James Q. Del Rosso, DO, FAOCD, and Hilary E. Baldwin, MD, address misconceptions surrounding antibiotic resistance, discuss principles behind antibiotic stewardship, and detail their approaches in clinical practice. Listen to the podcast now.
 
From our Latest Issue
 
Dermatology Times cover
Why patient experience matters in healthcare collections
 
Risks of EHRs
 
Skincare product updates
 
ADVERTISEMENT
Do you know an individual whose revolutionary ideas have refined the practice of dermatology?
Help us identify physicians and researchers in the field of dermatology whose dedication to the field has resulted in successful innovations and has inspired, informed, or improved the treatment of patients with skin disorders. Nominate a leader today for the 2020 Giants of DermatologyTM recognition program.
 
JOB OPPORTUNITIES
 
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.